These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30735833)

  • 21. Esophagitis in Non-Small Cell Lung Carcinoma Treatment Caused by Pembrolizumab.
    Yoshida S; Miyamoto S; Naruse H; Ito J; Kinosita K; Kudo T; Hatanaka K; Yamamoto Y; Sakamoto N
    Am J Gastroenterol; 2020 Jan; 115(1):13. PubMed ID: 31356230
    [No Abstract]   [Full Text] [Related]  

  • 22. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
    Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
    Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe polyradiculoneuritis associated with the combination of ipilimumab and pembrolizumab in a lung cancer patient.
    Cho HS; Lee KY; Hu CJ; Chung CC
    Neurol India; 2018; 66(2):509-511. PubMed ID: 29547174
    [No Abstract]   [Full Text] [Related]  

  • 24. Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
    Simonsen AB; Kaae J; Ellebaek E; Svane IM; Zachariae C
    J Am Acad Dermatol; 2020 Nov; 83(5):1415-1424. PubMed ID: 32320766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eczematous reactions mimicking psoriasiform dermatitis induced by nivolumab for advanced lung cancer.
    Tanaka M; Hoashi T; Ichiyama S; Noro R; Seike M; Kubota K; Gemma A; Funasaka Y; Saeki H
    Australas J Dermatol; 2019 Feb; 60(1):e67-e68. PubMed ID: 29896926
    [No Abstract]   [Full Text] [Related]  

  • 26. Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.
    Gorospe L; García-Gómez-Muriel I; Pian-Arias HG; Gómez-Ramírez J; Rioja-Martín ME; Olmedo-García ME; Garrido-López P; Muñoz-Molina GM; Mezquita L
    Ann Thorac Surg; 2020 Jun; 109(6):e397-e399. PubMed ID: 31846639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
    Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
    Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
    Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I
    Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
    Blanchard A; Bouchard N
    Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?
    Facchinetti F; Majori M; Sabato M; Gnetti L; Tiseo M
    Immunotherapy; 2019 Feb; 11(3):161-166. PubMed ID: 30730279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
    Tamura T; Akimoto E; Matsumoto C; Mori S; Nishi T; Kudo K; Kuyama S
    J Thorac Oncol; 2018 Oct; 13(10):1606-1607. PubMed ID: 29730378
    [No Abstract]   [Full Text] [Related]  

  • 33. New drugs and new toxicities: pembrolizumab-induced myocarditis.
    Inayat F; Masab M; Gupta S; Ullah W
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29367376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
    Coscarart A; Martel J; Lee MP; Wang AR
    J Cutan Pathol; 2020 Mar; 47(3):275-279. PubMed ID: 31589773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
    Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
    [No Abstract]   [Full Text] [Related]  

  • 36. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
    J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyponatremia in a Patient With Cancer.
    Uppal NN; Wanchoo R; Barnett R; Sinha A; Jhaveri KD
    Am J Kidney Dis; 2020 Jan; 75(1):A15-A18. PubMed ID: 31864502
    [No Abstract]   [Full Text] [Related]  

  • 38. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
    Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
    Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dupilumab for the treatment of prurigo nodularis: A systematic review.
    Cao P; Xu W; Jiang S; Zhang L
    Front Immunol; 2023; 14():1092685. PubMed ID: 36742321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
    Huang M; Pietanza MC; Samkari A; Pellissier J; Burke T; Chandwani S; Kong F; Pickard AS
    Pharmacoeconomics; 2019 Jan; 37(1):105-116. PubMed ID: 30515719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.